Prodrugs of heteroaryl compounds

1. A compound having a structure according to Formula I:

wherein

a is 1;

R 2 is (═O), such that b is 0;

R 4 is NR 7 R 8 ;

R 6 is H; and

R 7 , R 8 , and R 5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and a structure according to formula IV;

wherein R 14 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids, and

wherein if R 8 is a structure according to Formula IV, then R 7 is H;

R 1 is a structure according to Formula II:

wherein

R 9 is H; and

R 10 and R 11 are —OH ;

wherein at least one member selected from R 5 , R 7 , and R 8 , alone or together with the atom to which it is covalently bonded, is a carbamate .

2. The compound according to claim 1 , wherein R 5 , R 7 , and R 8 are independently selected from H and a structure according to Formula IV.

3. The compound according to claim 2 , wherein R 14 is substituted or unsubstituted alkyl.

4. The compound according to claim 3 , wherein R 14 is unsubstituted alkyl.

5. The compound according to claim 3 , wherein R 14 is unsubstituted C 5 -C 16 alkyl.

6. The compound according to claim 5 , wherein R 14 is selected from n-pentyl, n-hexyl, n-heptyl, n-octyl, 2-ethyl-hexyl, n-nonyl, n-decyl, n-dodecyl and n-hexadecyl.

7. The compound according to claim 5 , wherein R 14 is n-heptyl.

8. The compound according to claim 2 , wherein

R 8 is a structure according to Formula IV; and

R 5 is H.

9. The compound according to claim 8 , wherein R 14 is selected from n-pentyl, n-hexyl, n-heptyl, n-octyl, 2-ethyl-hexyl, n-nonyl, n-decyl, n-dodecyl and n-hexadecyl.

10. A compound selected from the group N 4 -Amyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Hexyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Heptyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Octyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -(2-Ethylhexyl)oxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Nonyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Decyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Dodecyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, N 4 -Hexadecyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine, and N 4 -Heptyloxycarbonyl-α-2′-deoxy-5,6-dihydro-5-azacytidine.

11. A method for treating HIV comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1 .

12. The method of claim 11 , wherein said compound is given orally.

13. The method of claim 12 , wherein said compound is an enteric formulation.

14. The method of claim 13 , wherein said compound is delivered in an osmotic oral delivery device.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to Formula I of claim 1 .

16. The compound according to claim 3 , wherein R 14 is unsubstituted (C 6 -C 10 ) alkyl.

17. The compound according to claim 10 , wherein the compound is N 4 -heptyloxycarbonyl-β-2′-deoxy-5,6-dihydro-5-azacytidine.

18. The compound according to claim 10 , wherein the compound is N 4 -Heptyloxycarbonyl-α-2′-deoxy-5,6-dihydro-5-azacytidine.